Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Scientists develop a lead compound to fight chemotherapy-resistant prostate cancer

Scientists develop a lead compound to fight chemotherapy-resistant prostate cancer

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI may help predict tumor sensitivity to systemic cancer therapies

AI may help predict tumor sensitivity to systemic cancer therapies

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Novel inhibitor to fight metastatic prostate cancer shows promise

Novel inhibitor to fight metastatic prostate cancer shows promise

Magnetic nanomaterials may become the basis for new approach to treating liver fibrosis

Magnetic nanomaterials may become the basis for new approach to treating liver fibrosis

New drug combo promises help for triple negative breast cancer patients

New drug combo promises help for triple negative breast cancer patients

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Prostate cancer 'super responders' could live for two years or more on immunotherapy

Prostate cancer 'super responders' could live for two years or more on immunotherapy

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

Improving the efficiency of antiangiogenic and antifibrotic drug for treatment of lung cancer

Improving the efficiency of antiangiogenic and antifibrotic drug for treatment of lung cancer

Modern chemo more effective than second targeted hormone therapy against resistant prostate cancer

Modern chemo more effective than second targeted hormone therapy against resistant prostate cancer

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Study defines biomarker in response to treatment of castration-resistant prostate cancer

Study defines biomarker in response to treatment of castration-resistant prostate cancer

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Researchers discover secret communication hotline between breast cancers and normal cells

Researchers discover secret communication hotline between breast cancers and normal cells

New combination therapy for cancer cells could soon be a reality

New combination therapy for cancer cells could soon be a reality